Cargando…

Prevalence of neurodegenerative/demyelinating disorders in patients with achalasia

INTRODUCTION: Esophageal achalasia is a primary motility disorder. Although the exact pathogenesis is unknown, autoimmune, and neurodegenerative processes seem to be involved similarly to neurodegenerative and/or demyelinating disorders (NDDs). We hypothesized that the prevalence of NDD may be highe...

Descripción completa

Detalles Bibliográficos
Autores principales: Jerie, Martin, Vackova, Zuzana, Vojtech, Zdenek, Mares, Jan, Meluzinova, Eva, Krajciova, Jana, Vymazal, Josef, Cerna, Hana, Martinek, Jan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552774/
https://www.ncbi.nlm.nih.gov/pubmed/36304096
http://dx.doi.org/10.1515/tnsci-2022-0249
_version_ 1784806321993809920
author Jerie, Martin
Vackova, Zuzana
Vojtech, Zdenek
Mares, Jan
Meluzinova, Eva
Krajciova, Jana
Vymazal, Josef
Cerna, Hana
Martinek, Jan
author_facet Jerie, Martin
Vackova, Zuzana
Vojtech, Zdenek
Mares, Jan
Meluzinova, Eva
Krajciova, Jana
Vymazal, Josef
Cerna, Hana
Martinek, Jan
author_sort Jerie, Martin
collection PubMed
description INTRODUCTION: Esophageal achalasia is a primary motility disorder. Although the exact pathogenesis is unknown, autoimmune, and neurodegenerative processes seem to be involved similarly to neurodegenerative and/or demyelinating disorders (NDDs). We hypothesized that the prevalence of NDD may be higher among patients with achalasia and vice versa as the background pathogenetic mechanisms are similar. METHODS: This was a prospective, comparative questionnaire-based study. Patients with achalasia and patients with NDD were enrolled. Selected patients with achalasia were thoroughly examined by a neurologist and selected patients with NDD were examined by a gastroenterologist to confirm or rule out NDD or achalasia. We assessed the prevalence of both achalasia and NDD and compared them with their prevalence in general population. RESULTS: A total of 150 patients with achalasia and 112 patients with NDD were enrolled. We observed an increased prevalence of NDD among patients with achalasia (6.0% (9/150); 95% CI (confidence interval): 3.1–11.2%) as compared to the estimated 2.0% prevalence in general population (p = 0.003). Although 32 out of 112 patients (28.6%) with NDD reported dysphagia, we did not observe significantly increased prevalence of achalasia in these patients (1.8% (2/112) vs 0.8% in general population, p = 0.226). CONCLUSION: The prevalence of NDD was significantly higher among patients with achalasia (6.0%) compared to general population (2.0%), suggesting an association of these disorders. Large-volume studies are necessary to confirm this finding.
format Online
Article
Text
id pubmed-9552774
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher De Gruyter
record_format MEDLINE/PubMed
spelling pubmed-95527742022-10-26 Prevalence of neurodegenerative/demyelinating disorders in patients with achalasia Jerie, Martin Vackova, Zuzana Vojtech, Zdenek Mares, Jan Meluzinova, Eva Krajciova, Jana Vymazal, Josef Cerna, Hana Martinek, Jan Transl Neurosci Research Article INTRODUCTION: Esophageal achalasia is a primary motility disorder. Although the exact pathogenesis is unknown, autoimmune, and neurodegenerative processes seem to be involved similarly to neurodegenerative and/or demyelinating disorders (NDDs). We hypothesized that the prevalence of NDD may be higher among patients with achalasia and vice versa as the background pathogenetic mechanisms are similar. METHODS: This was a prospective, comparative questionnaire-based study. Patients with achalasia and patients with NDD were enrolled. Selected patients with achalasia were thoroughly examined by a neurologist and selected patients with NDD were examined by a gastroenterologist to confirm or rule out NDD or achalasia. We assessed the prevalence of both achalasia and NDD and compared them with their prevalence in general population. RESULTS: A total of 150 patients with achalasia and 112 patients with NDD were enrolled. We observed an increased prevalence of NDD among patients with achalasia (6.0% (9/150); 95% CI (confidence interval): 3.1–11.2%) as compared to the estimated 2.0% prevalence in general population (p = 0.003). Although 32 out of 112 patients (28.6%) with NDD reported dysphagia, we did not observe significantly increased prevalence of achalasia in these patients (1.8% (2/112) vs 0.8% in general population, p = 0.226). CONCLUSION: The prevalence of NDD was significantly higher among patients with achalasia (6.0%) compared to general population (2.0%), suggesting an association of these disorders. Large-volume studies are necessary to confirm this finding. De Gruyter 2022-10-10 /pmc/articles/PMC9552774/ /pubmed/36304096 http://dx.doi.org/10.1515/tnsci-2022-0249 Text en © 2022 Martin Jerie et al., published by De Gruyter https://creativecommons.org/licenses/by/4.0/This work is licensed under the Creative Commons Attribution 4.0 International License.
spellingShingle Research Article
Jerie, Martin
Vackova, Zuzana
Vojtech, Zdenek
Mares, Jan
Meluzinova, Eva
Krajciova, Jana
Vymazal, Josef
Cerna, Hana
Martinek, Jan
Prevalence of neurodegenerative/demyelinating disorders in patients with achalasia
title Prevalence of neurodegenerative/demyelinating disorders in patients with achalasia
title_full Prevalence of neurodegenerative/demyelinating disorders in patients with achalasia
title_fullStr Prevalence of neurodegenerative/demyelinating disorders in patients with achalasia
title_full_unstemmed Prevalence of neurodegenerative/demyelinating disorders in patients with achalasia
title_short Prevalence of neurodegenerative/demyelinating disorders in patients with achalasia
title_sort prevalence of neurodegenerative/demyelinating disorders in patients with achalasia
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9552774/
https://www.ncbi.nlm.nih.gov/pubmed/36304096
http://dx.doi.org/10.1515/tnsci-2022-0249
work_keys_str_mv AT jeriemartin prevalenceofneurodegenerativedemyelinatingdisordersinpatientswithachalasia
AT vackovazuzana prevalenceofneurodegenerativedemyelinatingdisordersinpatientswithachalasia
AT vojtechzdenek prevalenceofneurodegenerativedemyelinatingdisordersinpatientswithachalasia
AT maresjan prevalenceofneurodegenerativedemyelinatingdisordersinpatientswithachalasia
AT meluzinovaeva prevalenceofneurodegenerativedemyelinatingdisordersinpatientswithachalasia
AT krajciovajana prevalenceofneurodegenerativedemyelinatingdisordersinpatientswithachalasia
AT vymazaljosef prevalenceofneurodegenerativedemyelinatingdisordersinpatientswithachalasia
AT cernahana prevalenceofneurodegenerativedemyelinatingdisordersinpatientswithachalasia
AT martinekjan prevalenceofneurodegenerativedemyelinatingdisordersinpatientswithachalasia